Post by Confo Therapeutics

Confo Therapeutics has secured a €1M VLAIO grant to accelerate development of ultra-long-acting GPCR-targeting antibody therapeutics for metabolic and endocrine disorders. This funding strengthens our mission to deliver next-generation treatments with superior efficacy for chronic conditions like obesity. A big thank you to VLAIO for supporting innovation in Flanders! Learn more: https://lnkd.in/equbrDZ7 #ConfoTherapeutics #Innovation #GPCR #MetabolicHealth #Biotech #VLAIOGrant